Influenza Virus Vaccine in B-Cell Chronic Lymphocytic Leukaemia Patients
Despina A. Gribabis(National and Kapodistrian University of Athens), Gerassimos A. Pangalis(Athens Medical Center), Vassiliki A. Boussiotis(Beth Israel Deaconess Medical Center), Panayiotis Panayiotidis(National and Kapodistrian University of Athens), C Hannoun(Institut Pasteur)
Cited by 49
Related Papers
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|3k
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
|New England Journal of Medicine|2016|1.4k
PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation
|Nature Communications|2015|1.2k
Cloning of B7-2: a CTLA-4 Counter-Receptor That Costimulates Human T Cell Proliferation
|Science|1993|914
The complex role of tumor-infiltrating macrophages
|Nature Immunology|2022|859